ACOR Inflection Point !!

Discussion in 'Acorda Therapeutics' started by anonymous, May 28, 2019 at 9:10 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    A - A
    C- collection
    O - of
    R - rejects
     

  2. anonymous

    anonymous Guest

    Your dispensed cartons of 6,200 for the qtr implies rebates > 45%. Good luck with that, as your GTN will shrivel, like Habib’s brain in the desert sun.
     
  3. anonymous

    anonymous Guest

    The only thing over the horizon is your $4 share price.
     
  4. anonymous

    anonymous Guest

    Thank you !!! You tell it like it is !!! We are bouncing back today !!!!!
     
  5. anonymous

    anonymous Guest

    If your definition of bounce back is down 12% intraday at $5.30 then yes, you are bouncing back to the price the organizations performance deserves. $4 per share by Labor Day .
     
  6. anonymous

    anonymous Guest

    And just like that.. down 34% to $3.98 at 9:51am. Hang it up, and take it behind the shed. Your immature rah rah, MAGA, ballbusting rants just reinforce a team of juveniles, your focus on business was clouded by your hopes and nonsense on here. Hope and analysts forecasts are NOT a business strategy. So make your choice... be a 12 year old and spin an inflection point to buy this crash and burn or reflect back if you did all you could to support launch. Next stop... < $1.00. Potential delisting.
     
  7. anonymous

    anonymous Guest

    Boom... now down 50%... you will close under $3. An incredible Suck-cess
     
  8. anonymous

    anonymous Guest

    Dr Cohen did outstanding job, along with Lauren, at the financial telecon yesterday. Explained the role out and issues of Inbrija in precision. We have importantly adequate cash flow and developing national and international market that will blossom in year. That reason for the $17-$28 target. Imagine the % return if you buy in now and sell at $25? WOW !!!!!

    Be tankful for our Leadership and GO GO GO !!!!
     
  9. anonymous

    anonymous Guest

    Would hope you clowns would stop talking as the investor community has spoken. The only good job your leader did was offering excuses... more excuses than a prostitute going to jail.
     
  10. anonymous

    anonymous Guest

    Habib, if by outstanding job you mean having no real answers and offering no real guidance then yeah it was fantastic.

    Evidently investors heard something (or didn’t hear something) that caused your “rebound” to falter.

    Could be they know the rebate you have to give ESI for mediocre coverage.

    Could be they did the math on the rebate you have to give in general.

    Could be they aren’t buying the # of docs who have tried Inbrija and not written another Rx. That was a lame story BTW.

    I have to admit, i was even shocked. I figured $4 easy. Who knew you would dip into $2 range. Congratulations on your massive ball busting success!

    As others have told you, maybe it’s time to STFU on this site and get to work on things that matter.
     
  11. anonymous

    anonymous Guest

    ACOR had much much better days when it had those illegal Mexicans running med-affairs and development.

    What has Mr Blank done lately, other than collecting a fat paycheck?

    The lack of a robust pipeline is part of the reason we find ourselves with a 3+ dollars stock price
     
  12. anonymous

    anonymous Guest

    LOLOLOLOLOLOL
     
  13. anonymous

    anonymous Guest

    even I could afford Acorda with change leftover. By the way, who is the hottest worker we got?
     
  14. anonymous

    anonymous Guest

    The math is easy for analysts with NET$ , understanding of distribution costs, SGA, rebates to payers >45%. Speaks to weakness of the managed market team. You lost all your talent in that team, and you failed miserably at this launch, and what you launch with set trajectory for the life of the brand.
     
  15. anonymous

    anonymous Guest

    .... do you hear that? It’s silence of acceptance of a failure. Maybe these rank and file have been slapped with the reality of their employer. Run don’t walk to look for alternate opportunity... markets spoken... don’t be a zombie and follow your leadership aimlessly... they have failed you and investors and will likely not recover.
     
  16. anonymous

    anonymous Guest

    its past time for the BOD to make some changes.
    Ron & his sidekick Lauren need to go ASAP.

    Regulatory needs to be overhauled as well since they clearly don’t know how to work with the FDA.

    Get someone in Managed Care that knows how to contract.

    Get a new PR firm that can pump ACOR in the right venues using complete sentences and proper English.
     
  17. anonymous

    anonymous Guest

    Totally disagree, We have a strong PR presence in all media.
     
  18. anonymous

    anonymous Guest

    Who?
    Tierney, Felicia & Habib?
     
  19. anonymous

    anonymous Guest

    The fact alone you focus on reinforcing your strong PR presence, supports your ignorance. Your PR does not mean $#%!. Your biggest need is a functional / high performance commercial leadership team. Until you get to that point the only role of your PR team is to spin hopes and make excuses.
     
  20. anonymous

    anonymous Guest

    Yes. The PR Team work hard to drive up share price and work 24/7 for the rank&file. Yes ACOR might be even lower if not for hard work of PR Team to offsit the negative post by other. !!!!
    Who else work Sat midnite ??